Moderna MRNA
$254.19 +$12.73 (+5.27%)
Market closed · Nov 6, 8:20 pm ET · Last extended-hours $256.92 +1.07%
Open$245.40
Prev close$241.46
Day range$237.86 – $267.50
Volume16.33M
Market cap$101.48B
P/E (TTM)–
Dividend yield–
Earnings
Average move on report day±6.1%last 16 reports
Closed higher6 of 1638% of the time
Best reaction+13.5%
Worst reaction-21.0%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q2 | 31 Jul 2026 | Pre Market | ±11.3% | -5.35% | Within range |
| 2026/Q1 | 1 May 2026 | Pre Market | ±10.9% | -1.24% | Within range |
| 2025/Q4 | 13 Feb 2026 | Pre Market | ±11.6% | +5.29% | Within range |
| 2025/Q3 | 6 Nov 2025 | Pre Market | ±7.9% | +3.27% | Within range |
| 2025/Q2 | 1 Aug 2025 | Pre Market | ±12.3% | -6.61% | Within range |
| 2025/Q1 | 1 May 2025 | Pre Market | ±10.8% | -5.29% | Within range |
| 2024/Q4 | 14 Feb 2025 | Pre Market | ±12.6% | +3.35% | Within range |
| 2024/Q3 | 7 Nov 2024 | Pre Market | ±13.6% | -2.95% | Within range |
| 2024/Q2 | 1 Aug 2024 | Pre Market | ±8.3% | -21.01% | Bigger than priced |
| 2024/Q1 | 2 May 2024 | Pre Market | ±7.7% | +12.68% | Bigger than priced |
| 2023/Q4 | 22 Feb 2024 | None | ±9.8% | +13.53% | Bigger than priced |
| 2023/Q3 | 2 Nov 2023 | Pre Market | ±8.4% | -6.52% | Within range |
| 2023/Q2 | 3 Aug 2023 | None | ±7.5% | -0.25% | Within range |
| 2023/Q1 | 4 May 2023 | None | ±7.0% | +3.22% | Within range |
| 2022/Q4 | 23 Feb 2023 | None | ±7.2% | -6.70% | Within range |
| 2022/Q3 | 3 Nov 2022 | None | ±8.4% | -0.75% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q2
By business line
Fundamentals
Latest reported quarter: Q2, ended Jun 2026
Revenue$143.00M+4.4% YoY
Operating profit-$815.00M+10.1% YoY
Net profit-$782.00M+5.2% YoY
Diluted EPS-$1.97+7.5% YoY
Free cash flow-$563.00M+38.9% YoY
Operating cash flow-$526.00M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin22.8%
Operating margin-150.2%
Net margin-142.6%
Return on equity-39.0%
Return on assets-27.4%
Return on invested capital-36.2%
Current ratio2.29
Liabilities / assets38.3%
Cash & investments$5.14B
Total debt$1.24B
Net cash (debt)$3.90B
No comments yet — be the first to weigh in on MRNA.
Sign in to join the discussion.